Facioscapulohumeral muscular dystrophy and Charcot-Marie-Tooth neuropathy 1A - evidence for “double trouble” overlapping syndromes
- Olivia Schreiber†1,
- Peter Schneiderat†1,
- Wolfram Kress2,
- Bernd Rautenstrauss3,
- Jan Senderek1,
- Benedikt Schoser1 and
- Maggie C Walter1Email author
© Schreiber et al.; licensee BioMed Central Ltd. 2013
Received: 21 February 2013
Accepted: 12 September 2013
Published: 16 September 2013
We report on a patient with genetically confirmed overlapping diagnoses of CMT1A and FSHD. This case adds to the increasing number of unique patients presenting with atypical phenotypes, particularly in FSHD. Even if a mutation in one disease gene has been found, further genetic testing might be warranted in cases with unusual clinical presentation.
The reported 53 years old male patient suffered from walking difficulties and foot deformities first noticed at age 20. Later on, he developed scapuloperoneal and truncal muscle weakness, along with atrophy of the intrinsic hand and foot muscles, pes cavus, claw toes and a distal symmetric hypoesthesia. Motor nerve conduction velocities were reduced to 20 m/s in the upper extremities, and not educible in the lower extremities, sensory nerve conduction velocities were not attainable. Electromyography showed both, myopathic and neurogenic changes. A muscle biopsy taken from the tibialis anterior muscle showed a mild myopathy with some neurogenic findings and hypertrophic type 1 fibers. Whole-body muscle MRI revealed severe changes in the lower leg muscles, tibialis anterior and gastrocnemius muscles were highly replaced by fatty tissue. Additionally, fatty degeneration of shoulder girdle and straight back muscles, and atrophy of dorsal upper leg muscles were seen. Taken together, the presenting features suggested both, a neuropathy and a myopathy. Patient’s family history suggested an autosomal dominant inheritance.
Molecular testing revealed both, a hereditary motor and sensory neuropathy type 1A (HMSN1A, also called Charcot-Marie-Tooth neuropathy 1A, CMT1A) due to a PMP22 gene duplication and facioscapulohumeral muscular dystrophy (FSHD) due to a partial deletion of the D4Z4 locus (19 kb).
Molecular testing in hereditary neuromuscular disorders has led to the identification of an increasing number of atypical phenotypes. Nevertheless, finding the right diagnosis is crucial for the patient in order to obtain adequate medical care and appropriate genetic counseling, especially in the background of arising curative therapies.
KeywordsFacioscapulohumeral muscular dystrophy Charcot-Marie-Tooth neuropathy 1A Hereditary motor and sensory neuropathy Overlapping syndrome Double trouble
Hereditary motor and sensory neuropathy (HMSN), also called Charcot-Marie-Tooth (CMT) disease, is the most common inherited neuromuscular disorder with an estimated prevalence of 1:2,500 . Roughly one third of all cases are caused by an autosomal dominant inherited 1.5 Megabase (Mb) tandem duplication encompassing the peripheral myelin protein 22 gene (PMP22) on chromosome 17p11.2-12 which encodes an important component of peripheral nervous system myelin [2–4]. Phenotypically, patients show a symmetric and distally pronounced muscle weakness and sensory deficits affecting the feet and lower legs and, to a lesser extent, the hands and forearms. Progressive muscle atrophy results in “steppage” gait and secondary foot deformities and can lead to severe disablement. Sensory deficits and paraesthesia are usually less prominent than in other neuropathies. Electrophysiology is an important tool for diagnosis and classification into demyelinating CMT1 (motor conduction velocities (MCVs) of median nerve <38 m/s) and axonal CMT2 (median nerve MCV > 38 m/s). Supportive treatment includes rehabilitative therapy and surgical treatment of skeletal deformities and soft-tissue abnormalities in a multidisciplinary approach [5, 6]. Curative therapeutic options are under investigation.
Autosomal dominant facioscapulohumeral muscular dystrophy (FSHD) is the third most common muscular dystrophy with an estimated prevalence of about 1:20,000 in Europe . The four main diagnostic criteria defining FSHD are (1) onset in facial or shoulder muscles with sparing of extraocular, pharyngeal and lingual muscles and the myocardium, (2) facial weakness in more than half of the affected family members, (3) autosomal dominant inheritance and (4) evidence of a myopathic disease in electromyography and muscle biopsy . The causative gene defect in the large majority (>95%) of FSHD patients is a contraction of a repetitive element on chromosome 4q35 known as D4Z4 to 1 to 10 units (in healthy individuals 11 to 100 units). Because FSHD is apparently not due to a conventional mutation within a neighboring protein-coding gene, the exact pathophysiological mechanism of the repeat loss causing muscle disease is unknown . The phenotypic spectrum is wide, even in the same family, showing a great variability in the level of impairment and disease progression. Therefore, it is still a diagnostic challenge to correctly diagnose FSHD since a broad clinical diversity results from a shortened D4Z4 locus.
With the advent of new causative therapeutic options finding a patient’s correct diagnosis is essential. The case presented here shows a new phenotype of two overlapping neuromuscular diseases which emphasizes the diagnostic challenges.
The patient was clinically and electrophysiologically examined by the authors.
An open muscle biopsy was performed at the age of 21 after first clinical symptoms occurred. Standard histological examination was carried out as described previously  and the muscle biopsy specimens were revisited after disease progression.
Whole-body muscle magnetic resonance imaging (MRI) was performed using a 3.0-T MR system. A routine muscular protocol containing axial T1-weighted (T1w) spin echo sequences was used (slice thickness: 6 mm). The protocol additionally included coronal and axial planes at four levels covering the whole body. The left distal pelvic muscles and proximal femoral muscles could not be examined as the patient had a hip implant.
Using MLPA (Multiplex Ligation-dependent Probe Amplification)-analysis (MRC-Holland P033) the PMP22 gene was searched for deletions and duplications. FSHD diagnosis was established by Southern blot analysis for the D4Z4 locus as reported elsewhere . Furthermore, the mutation-hot spot region of the myotilin gene was examined by direct sequencing of exon 2 (NM_006790).
This case report was exempt as part of the patient’s standard care. The patient consented to all performed diagnostic analyses as part of a standard diagnostic work-up and care as well as the publication of his clinical data, images (clinical photographs, MRI, muscle biopsy) and videos. However, he preferred to have his face made unrecognizable on the photos. Additionally, his family members gave permission for publication of their medical histories.
Childhood and adolescence were reported normal. First clinical symptoms were noted at age 20 with pes cavus, claw toes and walking difficulties. During the 5th decade, weakness of arm elevation and distal weakness of hands affecting the dorsal interossei with reduced abduction in the metacarpophalangeal (MCP) joints and a weakness in thumb abduction occurred. The patient reported mild hypoesthesia of fingers and toes and he had marked difficulties to button up his shirt. He walked unaided and maximum walking distance was not impaired.
In summary, the patient presented with a scapuloperoneal weakness and atrophy, foot deformities along with sensorimotor demyelinating neuropathy and mild hyerCKemia.
Molecular analysis of the PMP22 gene showed the typical duplication encompassing the PMP22 gene on chromosome 17p11.2-12 confirming the diagnosis of CMT1A. No mutations were found in exon 2 of the myotilin gene. A shortened chromosome 4q-specific fragment of 19 kb in the D4Z4 locus (FSHD repeat) and the FSHD-related 4qA haplotype were observed leading to the diagnosis of FSHD.
Both hereditary sensorimotor neuropathy due to PMP22 duplication (CMT1A) and facioscapulohumeral muscular dystrophy (FSHD) due to a shortened fragment of the D4Z4 locus (19 kb) were identified in the described patient. To the best of our knowledge this is one of only three published cases describing coincidence of CMT1A and FSHD.
Recent epidemiological data suggest that the frequency of CMT1A is around 1:7,500  while the frequency of FSHD is estimated at 1:20,000 . Thus, the chance of being affected by both disorders is about 1:150,000,000.
In the patient’s family history his sister and her daughter were suggestive of CMT1A as well. However, since both parents have died and no DNA samples of further family members were available, segregation could not be proven. Our patient showed typical symptoms of this generalized, primarily demyelinating neuropathy with reduced nerve conduction velocities, distal hypoesthesia and distal muscle atrophy leading to steppage gait and foot deformities like pes cavus und claw toes .
Since additional features like proximal muscle weakness of the shoulder girdle, myopathic changes in muscle biopsy specimen and EMG analysis were suggestive of additional primary involvement of the skeletal muscle genetic analyses were extended to include frequent forms of muscular dystrophies and myopathies. FSHD diagnosis was established by Southern blot analysis for the D4Z4 locus showing contraction of the repeat (19 kb) and a FSHD-related 4qA haplotype. It remains unclear if FSHD results from a de novo mutation occurring in 10% to 30% of all cases  or from familial inheritance as we cannot rule out the possibility of an undiagnosed mild presentation in other family members. Until now, the pathogenic relevance of the D4Z4 deletion has not been fully clarified and has been questioned in recent studies . However, in addition to the clinical findings, electromyography in our patient revealed mild myopathic changes in proximal muscles along with the myopathic changes in the muscle biopsy specimen. Along with shortening of the D4Z4 locus to 19 kb on EcoRI + BlnI double digestion, FSHD is likely to be causative for the additional myopathy.
The classical FSHD phenotype was described in 1884 by Landouzy and Dejerine with facial weakness, shoulder girdle and pectoral muscle weakness and atrophy, in some cases resulting in subsequent impairment of pelvic and lower leg muscles . But clinical variability has long been recognized in neuromuscular disorders. This has become most obvious with the advent of molecular genetic testing showing that identical molecular defects can result in diverse clinical presentations. This is especially true for FSHD where several unusual phenotypes and atypical morphological features ranging from hyperCKemia, severe muscle pain, facial-sparing, hypertrophic cardiomyopathy, camptocormia, distal and axial myopathy, along with atypical morphological changes such as vacuolar and/or inflammatory myopathy, nemaline rods, and deficiency of complex III of the mitochondrial respiratory chain were reported [15–23]. Our patient provides further evidence for this variability by not fulfilling all four major diagnostic criteria for diagnosis of FSHD as described above . Autosomal dominant inheritance cannot be proven since the parents were not available for molecular testing, and facial weakness was not seen.
Interfamilial and intrafamilial clinical variability has also been observed in CMT [24, 25] including cases of demyelinating CMT with scapuloperoneal distribution of motor impairment reported in the 1980s [26, 27]. In contrast to our case, these cases were confined to clinical findings since molecular genetic testing was not yet available in the 1980s. Harding and Thomas described a constellation of clinical symptoms similar to our patient but with striking wasting of both deltoid muscles which is rather uncommon in FSHD so that we cannot exclude that this patient suffered from another scapuloperoneal myopathy.
In addition to stochastic effects, environmental influences, allelic variation, modifier genes, somatic mosaicism and complex genetic and environmental interactions , some of this variability might be caused by concomitant mutations in other genes for neuromuscular conditions. In FSHD, such overlapping syndromes have been described several times in literature. Association with pathogenic mutations in other genes have been reported in cases of patients with mitochondrial myopathy/FSHD, Becker muscular dystrophy/FSHD, Duchenne muscular dystrophy/FSHD, Leber’s hereditary optic neuropathy/FSHD and caveolinopathy/FSHD determining overlapping phenotypes [15, 29–33]. For CMT1A, concomitant mutations in the PMP22 gene and the Connexin32 gene (causing CMTX), the DMPK1 gene (DM1 myotonic dystrophy) and the ABCD1 gene (adrenomyeloneuropathy) have been described to produce peculiar phenotypes . In addition, a combination of CMTX with Becker muscular dystrophy has been reported , causing both, generalized weakness and CK elevation as typical phenotype for a muscular dystrophy as well as foot deformity, decreased tendon reflexes and sensory loss due to a mutation in the Connexin32 gene.
There is one further report similar to ours on one family suffering from CMT1A and FSHD . Auer-Grumbach et al. reported on this family affected by genetically confirmed CMT1A with scapuloperoneal motor deficit but conflicting data concerning the concomitant presence of FSHD. Co-segregation of FSHD in this family was unconvincing and haplotype analysis on chromosome 4q was not performed as it was not described in the paper. In contrast to our report, no muscle histology was performed and EMG revealed a mild chronic neurogenic pattern in proximal and distal muscles. However, our patient showed myopathic changes assessed by electromyography and muscle biopsy which further support the molecular diagnosis of FSHD.
In our patient a contracted fragment of 19 kb in the D4Z4 locus was detected. It is generally accepted that there is a correlation between clinical severity and size of the D4Z4 repeat: small repeats stand for early age at onset and severe clinical course, whereas larger repeats mean later age at onset and milder course . Although the patient reported here carries a repeat size usually expected to result in a moderately severe phenotype with onset in the 1st or 2nd decade, he showed only mild symptoms of shoulder girdle weakness developing in the second half of life without facial or proximal leg muscle impairment until now. There is no obvious explanation for the unexpectedly mild phenotype in our patient and in contrast, the association of FSHD with X-linked CMT and Duchenne muscular dystrophy leads to severe infantile phenotypes [31, 38]. Butefisch et al. described a further patient with the combination of CMT1A and FSHD in 1998 . This female patient inherited CMT1A from her father and FSHD from her mother and this comorbidity resulted in severe generalized weakness, respiratory insufficiency and early death. However, according to the information given in the paper, only the diagnosis of CMT1A was proven by molecular testing but not the FSHD, neither in the patient nor in relatives. Thus, we cannot exclude the possibility that another progressive muscular dystrophy might be causative for this devastating clinical course in this patient.
All in all, too few “double trouble” patients are known to draw significant conclusions on how concomitant genetic conditions modify each other’s severity and progression in these patients. Nevertheless, the number of cases with genetically proven double trouble is likely to increase with the availability of improved genetic testing and whole exome or genome sequencing methods. This will result in an even broader variety of atypical clinical pictures but may also help to understand interference at the phenotypic, genetic and epigenetic levels having a direct impact on medical care and genetic counseling.
Our case reports on a patient with genetically confirmed overlapping diagnoses of CMT1A and FSHD. It adds to the increasing number of unique patients presenting with atypical and overlapping phenotypes, particularly in FSHD. Even if a mutation in a disease gene has been found, further genetic testing might be warranted in cases with unusual clinical presentation having a direct impact on medical care and genetic counseling.
This study was exempt as part of the patient’s standard care. The patient consented to all performed diagnostic analyses as part of a standard diagnostic work-up and care as well as the publication of his clinical data, images (clinical photographs, MRI, muscle biopsy) and videos. However, he preferred to have his face made unrecognizable on the photos. Additionally, his family members gave permission for publication of their medical histories. A copy of the written consent is available for review by the Editor of this journal.
We wish to thank the patient and his family for participation in this study. We thank Dr. med. Eva Coppenrath and Dr. med. Christoph Degenhart, Dept. of Radiology, Ludwig-Maximilians-University Munich, for reviewing the whole-body muscle MRI. OS, PS, WK, BR, BS and MCW are members of the German network on muscular dystrophies (MD-NET, 01GM0887) funded by the German Federal Ministry of Education and Research (BMBF, Bonn, Germany). MD-NET is a partner of TREAT-NMD (EC, 6th FP, proposal no. 036825). The article processing charge was funded by the Ludwig-Maximilians-University Munich in the funding program Open Access Publishing.
- Reilly MM, Murphy SM, Laura M: Charcot-Marie-Tooth disease. J Peripher Nerv Syst. 2011, 16: 1-14.View ArticlePubMedGoogle Scholar
- Lupski JR, de Oca-Luna RM, Slaugenhaupt S, Pentao L, Guzzetta V, Trask BJ, Saucedo-Cardenas O, Barker DF, Killian JM, Garcia CA, et al: DNA duplication associated with Charcot-Marie-Tooth disease type 1A. Cell. 1991, 66: 219-232. 10.1016/0092-8674(91)90613-4.View ArticlePubMedGoogle Scholar
- Raeymaekers P, Timmerman V, Nelis E, De Jonghe P, Hoogendijk JE, Baas F, Barker DF, Martin JJ, De Visser M, Bolhuis PA, et al: Duplication in chromosome 17p11.2 in Charcot-Marie-Tooth neuropathy type 1a (CMT 1a). The HMSN Collaborative Research Group. Neuromuscul Disord. 1991, 1: 93-97. 10.1016/0960-8966(91)90055-W.View ArticlePubMedGoogle Scholar
- Gess B, Schirmacher A, Boentert M, Young P: Charcot-Marie-Tooth disease: frequency of genetic subtypes in a German neuromuscular center population. Neuromuscul Disord. 2013, 23: 647-651. 10.1016/j.nmd.2013.05.005.View ArticlePubMedGoogle Scholar
- Pareyson D, Marchesi C: Diagnosis, natural history, and management of Charcot-Marie-Tooth disease. Lancet Neurol. 2009, 8: 654-667. 10.1016/S1474-4422(09)70110-3.View ArticlePubMedGoogle Scholar
- Young P, De Jonghe P, Stogbauer F, Butterfass-Bahloul T: Treatment for Charcot-Marie-Tooth disease. Cochrane Database Syst Rev. 2008, 1: CD006052-PubMedGoogle Scholar
- Orrell RW: Facioscapulohumeral dystrophy and scapuloperoneal syndromes. Handb Clin Neurol. 2011, 101: 167-180.View ArticlePubMedGoogle Scholar
- Padberg GW, Lunt PW, Koch M, Fardeau M: Diagnostic criteria for facioscapulohumeral muscular dystrophy. Neuromuscul Disord. 1991, 1: 231-234. 10.1016/0960-8966(91)90094-9.View ArticlePubMedGoogle Scholar
- Neguembor MV, Gabellini D: In junk we trust: repetitive DNA, epigenetics and facioscapulohumeral muscular dystrophy. Epigenomics. 2010, 2: 271-287. 10.2217/epi.10.8.View ArticlePubMedGoogle Scholar
- Weis J, Schroder JM: Adult polyglucosan body myopathy with subclinical peripheral neuropathy: case report and review of diseases associated with polyglucosan body accumulation. Clin Neuropathol. 1988, 7: 271-279.PubMedGoogle Scholar
- de Greef JC, Lemmers RJ, van Engelen BG, Sacconi S, Venance SL, Frants RR, Tawil R, van der Maarel SM: Common epigenetic changes of D4Z4 in contraction-dependent and contraction-independent FSHD. Hum Mutat. 2009, 30: 1449-1459. 10.1002/humu.21091.View ArticlePubMedGoogle Scholar
- Lemmers RJ, van der Wielen MJ, Bakker E, Padberg GW, Frants RR, van der Maarel SM: Somatic mosaicism in FSHD often goes undetected. Ann Neurol. 2004, 55: 845-850. 10.1002/ana.20106.View ArticlePubMedGoogle Scholar
- Scionti I, Greco F, Ricci G, Govi M, Arashiro P, Vercelli L, Berardinelli A, Angelini C, Antonini G, Cao M, et al: Large-scale population analysis challenges the current criteria for the molecular diagnosis of fascioscapulohumeral muscular dystrophy. Am J Hum Genet. 2012, 90: 628-635. 10.1016/j.ajhg.2012.02.019.View ArticlePubMedPubMed CentralGoogle Scholar
- Landouzy L, Déjerine J: De la myopathie atrophique progressive (myopathie héréditaire débutant dans l’enfance, par la face sans altération du système nerveux). C R Seances Acad Sci. 1884, 98: 53-58.Google Scholar
- Slipetz DM, Aprille JR, Goodyer PR, Rozen R: Deficiency of complex III of the mitochondrial respiratory chain in a patient with facioscapulohumeral disease. Am J Hum Genet. 1991, 48: 502-510.PubMedPubMed CentralGoogle Scholar
- Bushby KM, Pollitt C, Johnson MA, Rogers MT, Chinnery PF: Muscle pain as a prominent feature of facioscapulohumeral muscular dystrophy (FSHD): four illustrative case reports. Neuromuscul Disord. 1998, 8: 574-579. 10.1016/S0960-8966(98)00088-1.View ArticlePubMedGoogle Scholar
- Felice KJ, North WA, Moore SA, Mathews KD: FSH dystrophy 4q35 deletion in patients presenting with facial-sparing scapular myopathy. Neurology. 2000, 54: 1927-1931. 10.1212/WNL.54.10.1927.View ArticlePubMedGoogle Scholar
- Wood-Allum C, Brennan P, Hewitt M, Lowe J, Tyfield L, Wills A: Clinical and histopathological heterogeneity in patients with 4q35 facioscapulohumeral muscular dystrophy (FSHD). Neuropathol Appl Neurobiol. 2004, 30: 188-191. 10.1046/j.0305-1846.2003.00520.x.View ArticlePubMedGoogle Scholar
- Zouvelou V, Manta P, Kalfakis N, Evdokimidis I, Vassilopoulos D: Asymptomatic elevation of serum creatine kinase leading to the diagnosis of 4q35 facioscapulohumeral muscular dystrophy. J Clin Neurosci. 2009, 16: 1218-1219. 10.1016/j.jocn.2008.12.004.View ArticlePubMedGoogle Scholar
- Tsuji M, Kinoshita M, Imai Y, Kawamoto M, Kohara N: Facioscapulohumeral muscular dystrophy presenting with hypertrophic cardiomyopathy: a case study. Neuromuscul Disord. 2009, 19: 140-142. 10.1016/j.nmd.2008.11.011.View ArticlePubMedGoogle Scholar
- Reilich P, Schramm N, Schoser B, Schneiderat P, Strigl-Pill N, Muller-Hocker J, Kress W, Ferbert A, Rudnik-Schoneborn S, Noth J, et al: Facioscapulohumeral muscular dystrophy presenting with unusual phenotypes and atypical morphological features of vacuolar myopathy. J Neurol. 2010, 257: 1108-1118. 10.1007/s00415-010-5471-1.View ArticlePubMedGoogle Scholar
- Kottlors M, Kress W, Meng G, Glocker FX: Facioscapulohumeral muscular dystrophy presenting with isolated axial myopathy and bent spine syndrome. Muscle Nerve. 2010, 42: 273-275. 10.1002/mus.21722.View ArticlePubMedGoogle Scholar
- Jordan B, Eger K, Koesling S, Zierz S: Camptocormia phenotype of FSHD: a clinical and MRI study on six patients. J Neurol. 2011, 258: 866-873. 10.1007/s00415-010-5858-z.View ArticlePubMedGoogle Scholar
- Pareyson D, Scaioli V, Laura M: Clinical and electrophysiological aspects of Charcot-Marie-Tooth disease. Neuromolecular Med. 2006, 8: 3-22. 10.1385/NMM:8:1-2:3.View ArticlePubMedGoogle Scholar
- Birouk N, Gouider R, Le Guern E, Gugenheim M, Tardieu S, Maisonobe T, Le Forestier N, Agid Y, Brice A, Bouche P: Charcot-Marie-Tooth disease type 1A with 17p11.2 duplication. Clinical and electrophysiological phenotype study and factors influencing disease severity in 119 cases. Brain. 1997, 120: 813-823. 10.1093/brain/120.5.813.View ArticlePubMedGoogle Scholar
- Ronen GM, Lowry N, Wedge JH, Sarnat HB, Hill A: Hereditary motor sensory neuropathy type I presenting as scapuloperoneal atrophy (Davidenkow syndrome) electrophysiological and pathological studies. Can J Neurol Sci. 1986, 13: 264-266.PubMedGoogle Scholar
- Harding AE, Thomas PK: Distal and scapuloperoneal distributions of muscle involvement occurring within a family with type I hereditary motor and sensory neuropathy. J Neurol. 1980, 224: 17-23. 10.1007/BF00313203.View ArticlePubMedGoogle Scholar
- Zlotogora J: Penetrance and expressivity in the molecular age. Genet Med. 2003, 5: 347-352. 10.1097/01.GIM.0000086478.87623.69.View ArticlePubMedGoogle Scholar
- Filosto M, Tonin P, Scarpelli M, Savio C, Greco F, Mancuso M, Vattemi G, Govoni V, Rizzuto N, Tupler R, Tomelleri G: Novel mitochondrial tRNA Leu(CUN) transition and D4Z4 partial deletion in a patient with a facioscapulohumeral phenotype. Neuromuscul Disord. 2008, 18: 204-209. 10.1016/j.nmd.2007.12.005.View ArticlePubMedGoogle Scholar
- Rudnik-Schoneborn S, Weis J, Kress W, Hausler M, Zerres K: Becker’s muscular dystrophy aggravating facioscapulohumeral muscular dystrophy–double trouble as an explanation for an atypical phenotype. Neuromuscul Disord. 2008, 18: 881-885. 10.1016/j.nmd.2008.06.387.View ArticlePubMedGoogle Scholar
- Korngut L, Siu VM, Venance SL, Levin S, Ray P, Lemmers RJ, Keith J, Campbell C: Phenotype of combined Duchenne and facioscapulohumeral muscular dystrophy. Neuromuscul Disord. 2008, 18: 579-582. 10.1016/j.nmd.2008.03.011.View ArticlePubMedGoogle Scholar
- Chuenkongkaew WL, Lertrit P, Limwongse C, Nilanont Y, Boonyapisit K, Sangruchi T, Chirapapaisan N, Suphavilai R: An unusual family with Leber’s hereditary optic neuropathy and facioscapulohumeral muscular dystrophy. Eur J Neurol. 2005, 12: 388-391. 10.1111/j.1468-1331.2004.01060.x.View ArticlePubMedGoogle Scholar
- Ricci G, Scionti I, Ali G, Volpi L, Zampa V, Fanin M, Angelini C, Politano L, Tupler R, Siciliano G: Rippling muscle disease and facioscapulohumeral dystrophy-like phenotype in a patient carrying a heterozygous CAV3 T78M mutation and a D4Z4 partial deletion: Further evidence for “double trouble” overlapping syndromes. Neuromuscul Disord. 2012, 22: 534-540. 10.1016/j.nmd.2011.12.001.View ArticlePubMedPubMed CentralGoogle Scholar
- Hodapp JA, Carter GT, Lipe HP, Michelson SJ, Kraft GH, Bird TD: Double trouble in hereditary neuropathy: concomitant mutations in the PMP-22 gene and another gene produce novel phenotypes. Arch Neurol. 2006, 63: 112-117. 10.1001/archneur.63.1.112.View ArticlePubMedGoogle Scholar
- Bergmann C, Senderek J, Hermanns B, Jauch A, Janssen B, Schroder JM, Karch D: Becker muscular dystrophy combined with X-linked Charcot-Marie-Tooth neuropathy. Muscle Nerve. 2000, 23: 818-823. 10.1002/(SICI)1097-4598(200005)23:5<818::AID-MUS23>3.0.CO;2-O.View ArticlePubMedGoogle Scholar
- Auer-Grumbach M, Wagner K, Strasser-Fuchs S, Loscher WN, Fazekas F, Millner M, Hartung HP: Clinical predominance of proximal upper limb weakness in CMT1A syndrome. Muscle Nerve. 2000, 23: 1243-1249. 10.1002/1097-4598(200008)23:8<1243::AID-MUS13>3.0.CO;2-Z.View ArticlePubMedGoogle Scholar
- Lunt PW, Jardine PE, Koch MC, Maynard J, Osborn M, Williams M, Harper PS, Upadhyaya M: Correlation between fragment size at D4F104S1 and age at onset or at wheelchair use, with a possible generational effect, accounts for much phenotypic variation in 4q35-facioscapulohumeral muscular dystrophy (FSHD). Hum Mol Genet. 1995, 4: 951-958. 10.1093/hmg/4.5.951.View ArticlePubMedGoogle Scholar
- Lecky BR, MacKenzie JM, Read AP, Wilcox DE: X-linked and FSH dystrophies in one family. Neuromuscul Disord. 1991, 1: 275-278. 10.1016/0960-8966(91)90101-W.View ArticlePubMedGoogle Scholar
- Butefisch CM, Lang DF, Gutmann L: The devastating combination of Charcot-Marie-Tooth disease and facioscapulohumeral muscular dystrophy. Muscle Nerve. 1998, 21: 788-791. 10.1002/(SICI)1097-4598(199806)21:6<788::AID-MUS11>3.0.CO;2-P.View ArticlePubMedGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2350/14/92/prepub